Skip to main content

Table 4 ASCVD risk in obese individuals with different levels of Cer d18:1/24:1

From: Ceramide d18:1/24:1 as a potential biomarker to differentiate obesity subtypes with unfavorable health outcomes

 

Group 1 (N = 24) (Mean ± SD)

Group 2 (N = 25) (Mean ± SD)

P

Sex (Male : Female)

13:11

8:17

0.1171

age (year)

31.79 ± 9.55

29.68 ± 7.44

0.3913

BMI (kg/m2)

35.38 ± 4.62

37.75 ± 7.29

0.1833

SBP (mmHg)

134.58 ± 19.11

143.08 ± 17.28

0.1093

DBP (mmHg)

83.79 ± 10.48

91.44 ± 13.50

0.0323

WC (cm)

108.71 ± 11.76

108.98 ± 12.88

0.9403

ALT (U/L)

61.91 ± 50.85

76.09 ± 52.01

0.3082

AST (U/L)

38.82 ± 24.93

52.52 ± 32.82

0.2152

TG (mg/dL)

148.96 ± 112.74

188.90 ± 105.28

0.0872

TC (mg/dL)

187.55 ± 40.93

205.27 ± 33.63

0.1043

LDL-c (mg/dL)

120.22 ± 34.31

136.39 ± 26.31

0.0703

HDL-c (mg/dL)

44.33 ± 8.50

41.71 ± 7.79

0.2653

Lp(a) (mg/L)

185.48 ± 188.97

164.56 ± 184.88

0.9522

GIR30

4.70 ± 1.70

4.22 ± 1.43

0.5032

FPG (mg/dL)

102.01 ± 27.37

112.97 ± 32.83

0.1902

SCr (µmol/L)

66.26 ± 11.45

60.62 ± 12.61

0.1083

BUN(mmol/L)

4.59 ± 1.14

4.54 ± 1.08

0.8653

UA(µmol/L)

407.11 ± 93.64

404.49 ± 93.41

0.9223

10-year ASCVD risk(%)

1.43 ± 2.60

2.00 ± 2.92

0.4773

Lifetime ASCVD risk (%)

23.46 ± 9.24

32.6 ± 13.68

0.0093

  1. Group 1 included obese participants with a Cer d18:1/24:1 level below the median of the study population (898.29-1987.69 nmol/L). Group 2 included obese participants with a Cer d18:1/24:1 level above the median of the study population (1990.50-4491.76nmol/L). The continuous variables between two groups that were normally distributed were compared via Student’s t test
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X